Please assess the completion status of the following clinical trial:

Trial Title: A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~- Adult patients with histologically or cytologically confirmed cholangiocarcinoma at the time of diagnosis.~Patients with cancers of the gallbladder or ampulla of Vater are not eligible.~- Patients must have received at least one prior regimen containing gemcitabine with or without cisplatin for advanced/ metastatic disease. Patient should have evidence of progressive disease following prior regimen, or if prior treatment discontinued due to toxicity must have continued evidence of measurable or evaluable disease.~Exclusion criteria:~* Prior or current treatment with a MEK inhibitor (all Cohorts), BGJ398 (infigratinib) (all Cohorts), or selective FGFR inhibitor (Cohorts 1 and 2 only).~* insufficient organ function~  * Absolute Neutrophil Count (ANC) \< 1,000/mm3 \[1.0 x 10\^9/L\]~ * Platelets \< 75,000/mm3 \[75 x 10\^9/L\]~ * Hemoglobin \< 109.0 g/dL~ * Total bilirubin \> 1.5x upper limit of normal (ULN)~ * Aspartate aminotransferase/glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase/glutamic pyruvic transaminase (ALT/SGPT) \> 2.5x ULN (AST and ALT \> 5x ULN in the presence of liver metastases)~ * Serum creatinine \> 1.5x ULN and a calculated or measured creatinine clearance \< 45 mL/min~ * Inorganic phosphorus outside of normal limits~ * Total and ionized serum calcium outside of normal limits~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BGJ398 (infigratinib) (Type: EXPERIMENTAL): To estimate the anti-tumor activity of BGJ398 (infigratinib)

Based on this trial design, predict the completion outcome and termination type (if applicable).